Annual Research Productivity Report

TEXAS TECH UNIVERSITY
HEALTH SCIENCES CENTER™
EL PASO
Paul L. Foster School of Medicine
Department of Internal Medicine

Department of Internal Medicine
FY 2020
1 September 2019 – 30 June 2020

Prepared by: Sean M. Connery
Dear Friends—

I am very pleased to bring to you the Department of Internal Medicine’s Annual Research Productivity Report for FY20. Please note the abbreviated 10-month reporting period this year to better time with reporting for accreditation of our residency and fellowship programs.

First of all, let me take this opportunity to thank our faculty, residents and fellows for their hard work and clinical service during these challenging times in our community with the COVID-19 pandemic. In addition, our research efforts did not escape the challenges that came with the COVID-19 but we weathered the storm well by shifting priorities and working remotely as needed. The Department had another productive year with 58 peer-reviewed publications, several textbook chapters and number of regional and national presentations. While the number of publications remains impressive and is an important metric, what impresses me is the quality of the articles and the high-impact journals they are published in. Let me take this opportunity to congratulate our faculty, residents and fellows, who despite an extremely busy clinical workload these past several months, continue to excel in other academic endeavors, namely teaching and research. I would also like to thank Dr. Jerzy Sarosiek for his tireless efforts to promote research amongst our faculty, residents and medical students and being a resource to them. Of note, I have created a separate category this year for COVID-19-related publications and online perspectives.

I am happy to note that our house staff remain very productive and reflect their commitment, enthusiasm and also mentoring/guidance by our program directors. Our faculty received research funding from both public and private sources, and the clinical research enterprise continues to grow under the stewardship of Mr. Sean Connery.

I hope next year Internal Medicine will be even more productive, and each and every one of us will need to put in the effort to make this possible. Of note, this year we have added a QR code to the front of this report which will take you to the electronic version of this report.

Finally, I wish all of you a fun and productive COVID-FREE fall season!

Debabrata Mukherjee, M.D., M.S.
Chair, Department of Internal Medicine
# Table of Contents

## FACULTY PEER REVIEW/PUBMED PUBLICATIONS
- **Journal Articles**: 4-6
- **Review – Meta Analysis**: 6-8
- **Case Reports**: 8
- **Editorial/Comment**: 8-9
- **Letter to the Editor**: 9
- **Books/Book Chapters**: 9-10
- **Multimedia**: 10-11
- **Abstracts**: 12-17

## RESIDENT & FELLOW RESEARCH ACTIVITY (PGY 1-6)
- **Journal Articles**: 18-19
- **Review – Meta Analysis**: 19-20
- **Letter to the Editor - Editorial**: 20
- **Case Reports**: 20-21
- **Books/Book Chapters**: 21
- **Abstracts**: 21-25

## OPEN, ACTIVE RESEARCH
- **Grant Funded FY20**: 26
  - Department Funded Pilot Small Projects: 27
- **Open, Active Clinical Trials**: 27-30
JOURNAL ARTICLES, ORIGINAL INVESTIGATIONS


**REVIEW - META ANALYSIS**


CASE REPORTS


EDITORIAL/COMMENTARY


Lessons from China and the UK - Perspective. *Int J Surg* 2020 May 4;78:156-159. PMID: 32442686


**LETTER TO THE EDITOR/JOURNAL ANNOUNCEMENTS**


**BOOKS/BOOK CHAPTERS**

**BOOKS:**

**BOOK CHAPTERS:**


**MULTIMEDIA/Online Publications**


**COVID – 19 related PUBLICATIONS/Perspectives**


6. **Mukherjee D:** COVID-19 and Thrombotic or Thromboembolic Disease  

7. **Mukherjee D:** Black Patients and White Patients With COVID-19  

8. **Mukherjee D:** Ventilation Techniques and Risk for Transmission of COVID-19  

9. **Mukherjee D:** Outcomes of Patients Hospitalized for COVID-19 and Cardiac Disease  

10. **Mukherjee D:** Controversy in Managing Acute MI in the COVID-19 Era  

---

**Abstracts**


30. Koch KL, Parkman HP, Van Natta ML, **McCallum RW**, Kuo B, **Sarosiek I**, et al. Effect Of Liquid And Solid Test Meals On Symptoms And Gastric Myoelectrical Activity In Patients With


47. Robles A; Umeanaeto O; Contreras A; Conwell D; Mendoza-Ladd A. Endoscopic Pancreatic Necrosectomy Technique: Know Your “How” to Justify Your “Why”: *Am J Gastroenterol* 114:S527-S528, October 2019.


Drug Refractory Gastroparesis Based on Pyloric Pathology, Clinical and Gastric Emptying Results? *Am J Gastroenterol* 114:S676-S677, October 2019.


JOURNAL ARTICLES, ORIGINAL INVESTIGATIONS


**REVIEW - META ANALYSIS**


**LETTER TO THE EDITOR/EDITORIALS/COMMENT**


**Case Reports:**


**Book Chapters and Books**


Abstracts


35. Robles A; Umeanaeto O; Contreras A; Conwell D; Mendoza-Ladd A. Endoscopic Pancreatic Necrosectomy Technique: Know Your “How” to Justify Your “Why”: *Am J Gastroenterol* 114:S527-S528, October 2019.


OPEN, ACTIVE, ONGOING RESEARCH

Investigator Initiated Research Studies

GRANT FUNDED FY20

  
  FY17 $382,500  
  FY18 $378,366  
  FY19 $374,151  
  FY20 $369,887  
  FY21 $365,627  
  =========  
  $1,870,531  

- Evaluation of mutation and gene expression profiles in breast cancers derived from Hispanic women - Alexander Philipovskiy, MD – UTEP Border Biomedical Research Center (BBRC) Sub-Award- National Institute on Minority Health and Health Disparities (NIH). 03/01/2020 – 02/28/2021 $40,000  

- Pathway Exploration and Analysis in Renal Lupus (PEARL) - Accelerating Medicines Partnership (AMP) – PI: F. Payan-Schober, MD, Sub-I A Ahmad, MD. Public-private partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), 10 biopharmaceutical companies and multiple non-profit organizations. NIH - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Allergy and Infectious Diseases (NIAID).  
  
  Start Up Phase July 2015 – Dec 2015 $9,333  
  Phase 0 Dec 2015 – May 2016 $12,401  
  Phase 1 Jan 2016- Aug 2016 $29,535  
  Phase 2 June 2017 – 31 May 2020 $66,290  
  =========  
  Total $117,559
Department of Internal Medicine Pilot Small Projects Funded - Cycle 10-11.

- Dr. Tamis Bright: **Bone Density and Aromatase Inhibitors**
- Dr. Harsha S. Nagarajarao: **A 5-Year Retrospective Analysis for Congenital Coronary Artery Anomalies in Adult Patients of Hispanic Origin at the University Medical Center of El Paso**
- Dr. Alexander Philipovskiy: **Study of the relationship between the tumor gene-expression profiles and the response to neoadjuvant chemotherapy in patients with local or locally advanced breast cancer**
- Dr. Irene Sarosiek: **Endocannabinoid gene polymorphisms in diabetic gastroparesis: a case control study**
- Dr. Marc Zuckerman: **The epidemiology of functional gastrointestinal disorders on the U.S Mexico Border based on Rome IV criteria**

**Pharmaceutically Sponsored Clinical Research Studies Open, Active Clinical Trials**

- **A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC-0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA-Mutant, Hormone Receptor Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer.** Pharmaceutical Sponsor: Genentech, Inc. Roche Group, Syneos Health, LLC, F. Hoffmann-La Roche Ltd. Site Investigator: Alexander Philipovskiy, MD

- **Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19.** Mayo Clinic. Site Investigator: Harold Hughes, MD

- **A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease (INCREASE Study).** Pharmaceutical Sponsor: United Therapeutics Corporation. Site Investigator: Hernando Garcia, MD – Debabrata Mukherjee, MD

- **An Open-Label Extension study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease. (INCREASE Extension)** Pharmaceutical Sponsor: United Therapeutics Corporation. Site Investigator: Hernando Garcia, MD - Debabrata Mukherjee, MD.

- Phase 2 Multicenter, Double-Blind, Placebo Controlled, Efficacy, Safety, and Pharmacokinetic Study of 2 Doses of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension (PAH) (PRIMEx Study). Pharmaceutical Sponsor: Complexa Inc. Site Investigator: Hernando Garcia, MD - Debabrata Mukherjee, MD

- A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects with Pulmonary Arterial Hypertension on Stable Background Therapy: (Extension to Study CXA-10-301). Pharmaceutical Sponsor: Complexa Inc. Site Investigator: Hernando Garcia, MD - Debabrata Mukherjee, MD


- A Phase 1, Single Dose PK And Safety Study With Ni-03 Followed By A Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study To Evaluate The Safety And Efficacy Of Ni-03 Compared To Placebo In Subjects With Chronic Pancreatitis. Pharmaceutical Sponsor: Stason Pharmaceuticals, Inc. Site Investigator: Antonio Mendoza Ladd, MD. Site Sub-Investigator: Marc Zuckerman, MD.

- A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients with Irritable Bowel Syndrome with Constipation. Pharmaceutical Sponsor: Ironwood Pharmaceuticals. Site Investigator: Marc Zuckerman, MD. Site Sub-Investigator: Antonio Mendoza Ladd, MD.
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors. Pharmaceutical Sponsor: Ironwood Pharmaceuticals. Site Investigator: Marc Zuckerman, MD. Site Sub-Investigator: Antonio Mendoza Ladd, MD.

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study of MD-7246 Administered Orally for 12 Weeks to Treat Abdominal Pain in Patients with Diarrhea-predominant Irritable Bowel Syndrome. Pharmaceutical Sponsor: Ironwood Pharmaceuticals. Site Investigator: Marc Zuckerman, MD. Site Sub-Investigator: Antonio Mendoza Ladd, MD.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of Adult Subjects With Symptomatic Idiopathic or Diabetic Gastroparesis. Pharmaceutical Sponsor: Takeda Pharm. Richard McCallum, MD. Site Sub-Investigator: Irene Sarosiek, MD.

A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis. Pharmaceutical Sponsor: Allergan Sales, LLC. Site Investigator: Richard McCallum, MD. Site Sub-Investigator: Irene Sarosiek, MD.

A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis. Pharmaceutical Sponsor: Allergan Sales, LLC. Site Investigator: Richard McCallum, MD. Site Sub-Investigator: Irene Sarosiek, MD.

A Randomized, Double-Blind Placebo-Controlled Scintigraphy Study to Investigate the Effect of CIN-102 on Gastric Emptying and Antral Contractility in Adults with Diabetic Gastroparesis. Pharmaceutical Sponsor: CinDome Pharma, Inc. Site Investigator: Richard McCallum, MD. Site Sub-Investigator: Irene Sarosiek, MD.

MoPill Gastrointestinal Pill Study (MoPill-GPS). Pharmaceutical Sponsor: Rock West Medical Devices, LLC. Site Investigator: Richard McCallum, MD. Site Sub-Investigator: Irene Sarosiek, MD.
- **A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis.** Pharmaceutical Sponsor: Allergan Sales, LLC. Site Investigator: Richard McCallum, MD. Site Sub-Investigator: Irene Sarosiek, MD.

- **A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis (AURORA 02 Study).** Pharmaceutical Sponsor: Aurinia Pharmaceuticals Inc. Site Investigator: Fernanda Payan-Schober, MD. Site Sub-Investigator: Adeel Ahmad, MD.